health pharma news today obesity drugs glp-1 today The next phase of the drug race Dozens of new obesity drugs

The authors also identified that liraglutide treatment reduced central inflammation and oxidative stress [48]

Pooling across the field, a 2025 meta-analysis of seven randomized controlled trials, covering 456 participants, reported a standardized mean difference of -0.72 for wrinkle reduction, though the analysis noted high heterogeneity between studies and that roughly 40% of trials had industry funding both factors that warrant caution in interpreting the pooled effect size

Research on GLP-1 receptor agonists and new GLP-1/GIP dual receptor agonists not only reveals their neuroprotective potential but also provides new hope for PD treatment

The link between long noncoding RNAs and depression

Mechanistically, a GH excess blocks signaling at the insulin receptor and at IRS-1 and mobilizes free fatty acids